Scarica l'app Stockscreener
5.49
0.90%
-0.05
Dopo l'orario di chiusura:
5.51
0.02
+0.36%
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Taysha Gene Therapies stock hits all-time high at 5.49 USD - Investing.com Australia
B of A Securities Initiates Coverage of Taysha Gene Therapies (TSHA) with Buy Recommendation - MSN
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Taysha Gene Therapies’ SWOT analysis: stock faces pivotal trial test By Investing.com - Investing.com Canada
Taysha Gene Therapies’ SWOT analysis: stock faces pivotal trial test - Investing.com
Taysha soars on FDA breakthrough therapy status for lead asset - MSN
Vestal Point and Ryan Wilder hold 6.3% of Taysha Gene Therapies (TSHA) - Stock Titan
RTW Investments and R. Wong report 20.7M shares in Taysha (NASDAQ: TSHA) - Stock Titan
Possible Bearish Signals With Taysha Gene Therapies Insiders Disposing Stock - Moomoo
Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026 - Insider Monkey
TSHA-102 construct design study advances Rett syndrome research at ASGCT 2026 - Traders Union
Taysha Gene Therapies, Inc. engages Rettsyndrome community at Patient First event - Traders Union
Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights - Insider Monkey
Taysha Gene Therapies Ramps Up Ahead of TSHA-102 BLA - TipRanks
Assessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent Volatility - Yahoo Finance
Taysha (TSHA) Q1 2026 Earnings Transcript - AOL.com
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2026 Earnings Call Transcript - Insider Monkey
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Exploring a Potential 77% Upside in the Biotech Sector - DirectorsTalk Interviews
Taysha outlines PPQ completion by Q4 2026 while targeting a TSHA-102 BLA option based on a 6-month interim analysis - MSN
Taysha (TSHA) Advances Clinical Development Strategy for TSHA-10 - GuruFocus
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Taysha Gene Therapies Q1 2026 earnings preview - MSN
Taysha Gene Therapies, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies Q1 Earnings Call Highlights - Yahoo Finance
Taysha Gene Therapies Q1 2026 Earnings Call Transcript - MarketBeat
Chardan Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Taysha Gene Therapies, Inc. Q1 2026 10-Q Report: Financial Statements, Results, and Key Disclosures - Minichart
TSHA: Pivotal trial dosing and regulatory milestones for TSHA-102 on track amid strong market demand - TradingView
Earnings call transcript: Taysha Gene Therapies Q1 2026 misses EPS and revenue targets - Investing.com Nigeria
Taysha Gene Therapies: Runway to Fund Planned Operating Expenses Into 2028 >TSHA - Moomoo
TSHA: Pivotal trial dosing on track, strong efficacy and safety, and cash runway into 2028 - TradingView
Taysha Gene Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Taysha Gene Therapies | 10-Q: Q1 2026 Earnings Report - Moomoo
Taysha Gene Therapies Reports Q1 2026 Results, Advances TSHA-102 Pivotal Trials and FDA BLA Submission for Rett Syndrome Therapy - Minichart
Rising R&D spend widens Taysha Gene Therapies (NASDAQ: TSHA) Q1 loss - Stock Titan
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
TSHA: Q1 2026 net loss widened to $42.4M as TSHA-102 pivotal trials advanced toward BLA submission - TradingView
Taysha Gene Therapies (NASDAQ: TSHA) widens Q1 loss but affirms TSHA-102 BLA pathway - Stock Titan
Taysha Gene Therapies Q1 net loss widens on higher R&D costs - TradingView
A 6-month trial readout could shape Taysha's gene therapy filing - Stock Titan
BRIEF-Taysha Gene Therapies Q1 Net Income USD -42.41 Million - TradingView
Taysha Gene Therapies stock hits 52-week high at 6.77 USD - Investing.com Australia
Taysha Gene earnings loom with pivotal trial data on horizon By Investing.com - Investing.com South Africa
Taysha Gene earnings loom with pivotal trial data on horizon - Investing.com
Taysha Gene Therapies stock hits 52-week high at 6.77 USD By Investing.com - Investing.com South Africa
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):